Global Cancer Cachexia Market Size Likely to Surpass at a CAGR of 5.1% By 2033

As per the current market research conducted by CMI Team, the global Cancer Cachexia Market size is expected to record a CAGR of 5.1% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 3.3 Billion. By 2033, the valuation is anticipated to reach USD 5.1 Billion.

Cancer Cachexia Market: Growth Factors and Dynamics

• Increasing Cancer Prevalence: The rising incidence and prevalence of cancer globally contribute significantly to the growth of the Cancer Cachexia market. With cancer being a leading cause of morbidity and mortality worldwide, the incidence of cancer-related cachexia is also on the rise. As cancer rates continue to increase, particularly in aging populations, the demand for effective cachexia management strategies grows accordingly.

• Growing Awareness and Diagnosis: There has been a growing awareness among healthcare professionals regarding the significance of early detection and management of cancer cachexia. Improved understanding of the underlying mechanisms of cachexia and its impact on patient outcomes has led to enhanced diagnostic strategies and earlier intervention. This increased awareness and diagnosis contribute to the expansion of the Cancer Cachexia market.

• Advancements in Treatment Approaches: Advances in oncology research have led to the development of novel treatment approaches for cancer cachexia. These include targeted therapies aimed at modulating specific molecular pathways involved in cachexia progression, such as inflammation, muscle wasting, and metabolic dysregulation. Additionally, there is ongoing research into personalized medicine approaches to tailor treatments based on individual patient characteristics, further driving market growth.

• Rising Healthcare Expenditure: The increasing healthcare expenditure, particularly in oncology and supportive care, is fueling the growth of the Cancer Cachexia market. Governments, healthcare providers, and insurance companies are investing in innovative therapies and supportive care services to improve patient outcomes and quality of life. This financial commitment to cancer care extends to the management of cachexia, driving market expansion.

• Collaborative Research Efforts: Collaborative research efforts involving academia, industry, and patient advocacy groups are playing a crucial role in advancing our understanding of cancer cachexia and developing new treatment modalities. Partnerships and collaborations facilitate the exchange of knowledge, resources, and expertise, accelerating the translation of scientific discoveries into clinical applications. These collaborative efforts contribute to market growth by fostering innovation and expanding the pipeline of potential cachexia therapies.

• Regulatory Initiatives and Incentives: Regulatory agencies are increasingly recognizing the importance of addressing supportive care needs, including cachexia, in cancer patients. Regulatory initiatives, such as expedited pathways for drug approval and incentives for orphan drug development, encourage investment in research and development targeting unmet medical needs like cancer cachexia. The availability of regulatory pathways and incentives incentivizes pharmaceutical companies to invest in developing innovative therapies for cachexia, driving market growth.

Cancer Cachexia Market: Partnership and Acquisitions

• In 2022, The team, led by Rutgers Cancer Institute of New Jersey, secured a USD 25 million Cancer Grand Challenges grant to study cancer cachexia, a debilitating condition prevalent in advanced cancer stages. This funding aims to advance understanding and develop effective interventions for cachexia management.

• In 2023, First Light Acquisition Group and Calidi Biotherapeutics, Inc. announced their merger to form a clinical-stage biotechnology company. Their focus is on developing oncolytic virotherapy using a stem cell-based cancer treatment delivery platform.

• In 2022, Gilead and Dragonfly have announced a research collaboration to advance natural killer cell engagers in oncology. Gilead obtained a worldwide license from Dragonfly for their 5T4 targeting immunotherapy program DF7001 as part of the agreement.

Report Scope

Cancer Cachexia Market: COVID-19 Analysis

The COVID-19 pandemic has had a significant impact on the Cancer Cachexia Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

• Disruption of Healthcare Services: The COVID-19 pandemic led to disruptions in healthcare services globally, including delays in cancer screenings, diagnosis, and treatments. As a result, many cancer patients face challenges in accessing timely care, including the management of cancer cachexia. The focus on managing COVID-19 patients and minimizing the risk of infection also diverted resources away from supportive care services for cancer patients, potentially exacerbating symptoms of cachexia.

• Clinical Trials Disruptions: Many clinical trials investigating novel therapies for cancer cachexia were either suspended or delayed due to the pandemic. Restrictions on patient recruitment, limitations on in-person visits, and prioritization of COVID-19-related research affected the progress of ongoing trials and hindered the initiation of new studies. This slowdown in clinical research could delay the development and approval of promising cachexia treatments, impacting the Cancer Cachexia market.

• Resumption of Healthcare Services: As COVID-19-related restrictions ease and healthcare systems stabilize, efforts to resume and prioritize cancer care services, including supportive care for cachexia, will be crucial. Healthcare facilities may implement strategies such as telemedicine, extended clinic hours, and streamlined processes to address the backlog of cancer diagnoses and treatments, ensuring timely management of cachexia.

• Focus on Patient Education and Support: Patient education and support programs can play a vital role in mitigating the impact of COVID-19 on cancer cachexia management. Healthcare providers can leverage telehealth platforms to deliver education on nutrition, physical activity, and symptom management to cancer patients remotely. Additionally, virtual support groups and counseling services can provide emotional and social support to patients experiencing cachexia-related challenges.

• Accelerated Research and Development: There may be increased focus and investment in research and development targeting cancer cachexia in the post-pandemic period. Pharmaceutical companies, academic institutions, and research organizations may prioritize the development of innovative therapies for cachexia, leveraging insights gained from COVID-19 research and therapeutic developments. Expedited regulatory pathways and funding incentives may further stimulate R&D efforts in this area.

In conclusion, the COVID-19 pandemic has had a mixed impact on the Cancer Cachexia Market, with some challenges and opportunities arising from the pandemic.

List of the prominent players in the Cancer Cachexia Market:

• Pfizer Inc.
• Novartis International AG
• Merck & Co. Inc.
• Eli Lilly and Company
• Bristol Myers Squibb Company
• AstraZeneca PLC
• Hoffmann-La Roche Ltd.
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• GlaxoSmithKline plc
• Bayer AG
• Boehringer Ingelheim International GmbH
• Sanofi SA
• AbbVie Inc.
• Johnson & Johnson
• Others

The Cancer Cachexia Market is segmented as follows:

By Therapeutics

• Progestogen
• Corticosteroid
• Combination Therapy
• Other Therapeutics

By Mechanism Of Action

• Appetite Stimulators
• Weight Loss Stabilizers
• Others

By Distribution Channel

• Hospital Store
• Retail Pharmacy Store
• Online Pharmacies

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America